The European Commission has granted approval to United Kingdom-based AstraZeneca for its Fasenra (benralizumab) as an add-on maintenance treatment for patients with severe eosinophilic asthma.
It was reported yesterday that the approval is for the treatment of adult patients in whom the condition is inadequately controlled even after being subjected to high-dose inhaled corticosteroids and long-acting beta-agonists. It was granted based on the findings of the WINDWARD study, comprised of six phase 3 trials including the pivotal SIROCCO and CALIMA exacerbation trials, and the OCS-sparing trial, ZONDA.
The product is a monoclonal antibody that uses natural killer cells to induce direct, fast and almost-complete depletion of eosinophils. Fasenra, which was developed by AstraZeneca with its global biologics research and development arm MedImmune, was approved in the US in November 2017 for the treatment of severe eosinophilic asthma.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval